Follow @TheHPRA
Contact us
Glossary
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Lartruvo (olaratumab) - Important Safety Information from Eli Lilly & Company as approved by the HPRA
Notice type:
3rd Party Publications
Date:
31/01/2019
Problem Or Issue:
Important Safety Information communication from Eli Lilly & Company - Lartruvo (olaratumab): outcome of required post-approval study did not confirm the clinical benefit of olaratumab in the approved indication.
Important Safety Information - Lartruvo (olaratumab)
« Back
Date Printed: 05/07/2022